Vascular Endothelial Growth Factor Receptor-2
"Vascular Endothelial Growth Factor Receptor-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 200-230-kDa tyrosine kinase receptor for vascular endothelial growth factors found primarily in endothelial and hematopoietic cells and their precursors. VEGFR-2 is important for vascular and hematopoietic development, and mediates almost all endothelial cell responses to VEGF.
| Descriptor ID |
D040301
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.200 D12.776.543.750.630.750.200 D12.776.543.750.750.400.910.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor Receptor-2- Vascular Endothelial Growth Factor Receptor-2
- Vascular Endothelial Growth Factor Receptor 2
- KDR Tyrosine Kinase
- Tyrosine Kinase, KDR
- VEGFR-2
- Fetal Liver Kinase-1
- Fetal Liver Kinase 1
- Kinase Insert Domain Receptor
- VEGF Receptor Flk-1
- Flk-1, VEGF Receptor
- VEGF Receptor Flk 1
- VEGF Receptor KDR
- KDR, VEGF Receptor
- Flk-1 Protein
- Flk 1 Protein
- Flk-1 Receptor Tyrosine Kinase
- Flk 1 Receptor Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-2".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-2".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2005 | 0 | 2 | 2 |
| 2006 | 2 | 6 | 8 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 3 | 4 |
| 2010 | 1 | 4 | 5 |
| 2011 | 0 | 2 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 3 | 3 | 6 |
| 2014 | 3 | 2 | 5 |
| 2015 | 2 | 2 | 4 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 3 | 4 |
| 2019 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-2" by people in Profiles.
-
MTOR maintains endothelial cell integrity to limit lung vascular injury. J Biol Chem. 2024 Dec; 300(12):107952.
-
Proteo-genomic characterization of virus-associated liver cancers reveals potential subtypes and therapeutic targets. Nat Commun. 2022 10 29; 13(1):6481.
-
Molecular analysis of knockdown resistance (kdr) mutations in the voltage-gated sodium channel gene of Aedes aegypti populations from Saudi Arabia. Parasit Vectors. 2022 Oct 19; 15(1):375.
-
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy. Clin Cancer Res. 2022 06 01; 28(11):2229-2236.
-
Angiosarcoma of the Pancreas in a Pediatric Patient With an Activating KDR-Internal Tandem Duplication: A Case Report and Review of the Literature. J Pediatr Hematol Oncol. 2022 Apr 01; 44(3):e751-e755.
-
Endothelial p130cas confers resistance to anti-angiogenesis therapy. Cell Rep. 2022 01 25; 38(4):110301.
-
Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. Nat Cardiovasc Res. 2022 01; 1(1):28-44.
-
CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Rep. 2021 08 17; 36(7):109549.
-
Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Sci Rep. 2021 04 30; 11(1):9362.
-
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021 04; 20(4):665-675.